Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CA
CAMP4 Therapeutics Corporation Common Stock
CAMP
Mkt Cap
$200.2M
Volume
76.76K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CA
CAMP
CA
CAMP4 Therapeutics Corporation Common Stock
CAMP
News
·
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
Mkt Cap
$216.5M
Volume
76.76K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
CAMP4 Therapeutics announced its participation in a panel discussion titled 'RNA Medicines: Transcriptome Engineering' at Chardan's 10th Annual Healthcare Conference on October 20, 2026. The panel will be held in New York and webcast live, with a 30-day replay available on CAMP4's investor relations website.
GlobeNewswire Inc. · Oct 14, 2026
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics granted non-qualified stock options to purchase 39,000 shares to three newly hired employees as inducement for employment. The options have a 10-year term, an exercise price of $3.96 per share, and will vest over four years with 25% vesting after one year followed by monthly installments.
GlobeNewswire Inc. · Jun 19, 2026
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics granted 8,000 non-qualified stock options to a newly hired employee on February 16, 2026, with an exercise price of $3.85 per share. The options vest over four years with a ten-year term, reflecting the company's continued hiring and growth in its RNA-targeting therapeutics pipeline.
GlobeNewswire Inc. · Feb 20, 2026
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
CAMP4 Therapeutics secured a private placement of up to $100 million to advance its first-in-class treatment for SYNGAP1-related disorders, with $50 million in upfront proceeds and potential additional funding contingent on clinical milestones.
GlobeNewswire Inc. · Sep 10, 2025
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
CAMP4 presented positive data from its SYNGAP1-related disorders and urea cycle disorders programs, including increased protein levels in non-human primates and favorable safety data from a Phase 1 trial.
GlobeNewswire Inc. · May 16, 2025
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
The angioedema treatment market is expected to grow due to the rising prevalence of allergic conditions and increasing awareness of hereditary angioedema (HAE). The pipeline analysis shows over 15 companies are developing 20+ angioedema drugs, with promising therapies in different clinical trial phases.
GlobeNewswire Inc. · May 6, 2025
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
CAMP4 Therapeutics, a clinical-stage biotech company, announced that it will present at the Piper Sandler 36th Annual Healthcare Conference in New York City on December 5, 2024. The company is developing regRNA-targeting therapeutics to upregulate gene expression and restore healthy protein levels for genetic diseases.
GlobeNewswire Inc. · Dec 2, 2024
CalAmp Reaches Comprehensive Agreement to Significantly Reduce Debt, Go Private, and Strengthen Financial Flexibility to Support Innovation Through a Consensual Financial Restructuring
CALAMP REACHES COMPREHENSIVE AGREEMENT TO SIGNIFICANTLY REDUCE DEBT, GO PRIVATE, AND STRENGTHEN FINANCIAL FLEXIBILITY
GlobeNewswire Inc. · Jun 3, 2024
American Superconductor (AMSC) Q4 Earnings and Revenues Surpass Estimates
American Superconductor (AMSC) delivered earnings and revenue surprises of 266.67% and 14.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 29, 2024
Ballard Power Systems (BLDP) Reports Q1 Loss, Misses Revenue Estimates
Ballard (BLDP) delivered earnings and revenue surprises of -7.69% and 12.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 7, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CA
CAMP
CAMP4 Therapeutics Corporation Common Stock
Buy
Sell
Market
Limit
Soon
CAMP
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CAMP yet.
Related Tickers
Earnings